Document Detail


Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases.
MedLine Citation:
PMID:  18458033     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The detection of viable podocytes in the urine of patients with proteinuric diseases has been described as a non-invasive method to monitor disease activity. Most of the published studies use podocalyxin (PDX) as a podocyte specific marker. METHODS: We examined the excretion of viable PDX-positive cells in a random set of spot urine from patients with biopsy-proven focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MGN) or membranoproliferative glomerulonephritis (MPGN) and characterized the excreted cells for podocyte and parietal epithelia markers as well as for proliferation activity. RESULTS: We found that untreated patients with active disease excrete high numbers of PDX-positive cells in their urine. In contrast to that we were not able to detect significant amounts of PDX-positive cells in the urine of patients with active minimal change disease (MCD) and patients with FSGS or MGN in full remission. When we further characterized the cells we rarely detected expression of podocyte specific markers in the PDX-positive cells, but at least 50% of the PDX-positive cells were double positive for cytokeratin (CK8-18). Immunohistochemistry of the corresponding renal biopsies showed that 100% of podocytes and parietal cells stained positive for PDX. Semiquantitative analysis revealed that 45% of parietal cells were positive for CK8-18 and 100% of proximal tubular cells. No cells of the glomerular epithelial layer stained positive for CK8-18. CONCLUSIONS: PDX-positive cells are lost in the urine in disease states that require podocyte regeneration and are a useful non-invasive marker for glomerular disease activity. These cells are possibly derived from the parietal epithelial layer.
Authors:
Johannes Achenbach; Michael Mengel; Irini Tossidou; Imke Peters; Joon-Keun Park; Marion Haubitz; Jochen H Ehrich; Hermann Haller; Mario Schiffer
Related Documents :
2464943 - Insulinlike growth factor-1 is a progression factor for human mesangial cells.
1698033 - Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogen...
14713103 - Melanoma invasion in reconstructed human skin is influenced by skin cells--investigatio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-05-05
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  23     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-18     Completed Date:  2009-02-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  3138-45     Citation Subset:  IM    
Affiliation:
Mario Schiffer, Division of Nephrology, Department of Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Case-Control Studies
Child
Child, Preschool
Female
Glomerulonephritis, Membranoproliferative / metabolism,  pathology,  urine*
Glomerulonephritis, Membranous / metabolism,  pathology,  urine*
Glomerulosclerosis, Focal Segmental / metabolism,  pathology,  urine*
Humans
Keratins / metabolism
Kidney / metabolism,  pathology
Male
Middle Aged
Podocytes / metabolism,  pathology*
Sialoglycoproteins / metabolism
Staining and Labeling
Urine / cytology
Young Adult
Chemical
Reg. No./Substance:
0/Sialoglycoproteins; 0/podocalyxin; 68238-35-7/Keratins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Towards improved cardiovascular management: the necessity of combining blood pressure and fluid over...
Next Document:  Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years.